### IAP5 Rec'd PCT/PTO 2 7 JAN 2886ENT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chengzhi Zhang, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/US2004/025480

Title: Benzofuran Derivatives Useful for Treating Hyper-Proliferative Disorders

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

### TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY 37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO]. A copy of the International Search Report is also enclosed for your reference.

# IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

### **FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

William F. Gray Reg. No.: 31,018

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane

West Haven, CT 06516 Telephone: (203) 812-2226 Facsimile: (203) 812-6459

# IAP5 Rec'd PCT/PTO 2 7 JAN 2006 10/566343

PTO/SB/08A (07-05)

Substitute for form 1449/PTO				Complete if Known		
				Application Number	[to be assigned]	
INIEC	DMATI	ON DISCI	OSLIDE	Filing Date		
-				First Named Inventor	Chengzhi Zhang	
STATEMENT BY APPLICANT				Art Unit		
(Use as many sheets as necessary)		Examiner Name	_			
Sheet	1	of	2	Attorney Docket Number	5168	

Examiner	Cito	Document Number	U. S. PATENT D Publication Date	Name of Patentee or	Degree Calverna Union Miles
Initials*	No.1	Number-Kind Code <sup>2</sup> (f Innum)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	_	US-	++		
		US-			
		IIS.			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Passages	Г
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°
/N.C./		WO 03/072561 A1	09-04-2003	Bayer Pharmaceuticals	Corporation	
/N.C	, F2	EP 0,731,097 A1	09-11-1996	Eli Lilly and Company		
/N.C.		11100				
						L
						г

"EXAMENEE I initial if reference considered, whether or not citation is in conformance with MPEP 609. They like through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicants\* unkipe citation designation number (optional.)\* See Kinds Codes of USPTO Patent Dearminst at www.septo.gov or MPEP 90.00 of. \*Enter Office that staused the document, by the two-helder code (WIPO Standard 37.3). \*For Applicants patent document, by the two-helder code (WIPO Standard 37.3). \*For the patent document, by the two-helder code (WIPO Standard 37.3). \*For the patent document, by the two-helder code (WIPO Standard 37.3). \*For the patent document, by the two-helder code (WIPO Standard 37.3). \*For the patent document code on the document under WIPO Standard 37.1 \*For the patent document or check mark here if English Indiquage.

Considered

Examiner Signature

the appropriate symbols as indicated on the occument union virvi C abused of the propriate symbols as indicated on the occument union virvi C abused of the propriate of the pro

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## IAP5 Rec'd PCT/PTO 27 JAN 2006

PTO/SB/08B (07-05) 07/31/2006. OMB 0651-0031

Und	er the Paperwork Re	duction Act	of 1995, no persons a	U.S. Patent re required to respond to a collection	and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number.		
Substitute	e for form 1449/PTO			Complete if Known			
Cubbinum	10 10 11 14421 10			Application Number	[to be assigned] / 566343		
			CLOSURE	Filing Date	*********		
STA	TEMENT E	BY AP	PLICANT	First Named Inventor	Chengzhi Zhang		
1	(Use as many sh	oots as noc	ossan/)	Art Unit			
	(23020)			Examiner Name			
Sheet	2	of	2	Attorney Docket Number	5168		

	-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
N.C./	R1	Hayakawa, I., et al., "4-Hydroxy-3-methyl-6-phenylbenzofuran-2-carboxylic Acid Ethyl Ester Derivatives as Potent Anti-tumor Agents", Bioorg. Med. Chem. Lett. 14: 455-458 (2004)	
/N.0	./ <sub>R2</sub>	Hayakawa, I., et al., "Thienopyridine and Benzofuran Derivatives as Potent Anti-tumor Agents Possessing Different Structure-activity Relationships", Bioorg. Med. Chem. Lett. 14: 3411-3414 (2004)	
/N.C./	R3	Hayakawa, I., et al., "A Library Synthesis of 4-Hydroxy-3-Methyl-6-Phenylbenzofuran-2-carboxylic Acid Ethyl Ester Derivatives as Anti-tumor Agents", Bioorg. Med. Chem. Lett. 14: 4383-4387 (2004)	
	_		

⊏xammer	I /Nizal Chandrakumar/	Date	04/20/2000
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Confidence include copy of the torm with next communication to applicate a check mark here of English Integrator Treatation is attached.

1. This collection of Intermedian is required by 37 CHz 11.8. In the information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFE 1.1.4. This collection is estimated to late 2 hours be applied within its office and by the USPTO to process) an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFE 1.1.4. This collection is estimated to late 2 hours to complete, including application, and solutioning the completed applications have been been applied to the completed application been been been applied to the completed application been been applied to the completed application by the process of the completed application been been applied to the completed application of the completed applicati